Silk Road Medical, Inc (NASDAQ:SILK) Shares Acquired by Bullseye Asset Management LLC

Bullseye Asset Management LLC boosted its stake in shares of Silk Road Medical, Inc (NASDAQ:SILKFree Report) by 17.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 131,718 shares of the company’s stock after purchasing an additional 20,000 shares during the period. Bullseye Asset Management LLC owned approximately 0.34% of Silk Road Medical worth $1,616,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Armistice Capital LLC acquired a new position in Silk Road Medical in the 4th quarter worth approximately $21,693,000. Bellevue Group AG grew its position in Silk Road Medical by 0.4% during the 4th quarter. Bellevue Group AG now owns 1,435,682 shares of the company’s stock worth $17,616,000 after purchasing an additional 5,120 shares during the period. Rubric Capital Management LP purchased a new position in shares of Silk Road Medical during the 4th quarter valued at about $17,520,000. Rings Capital Management LLC purchased a new position in shares of Silk Road Medical during the 4th quarter valued at about $10,552,000. Finally, Parkman Healthcare Partners LLC lifted its holdings in shares of Silk Road Medical by 118.7% in the 4th quarter. Parkman Healthcare Partners LLC now owns 545,235 shares of the company’s stock valued at $6,690,000 after buying an additional 295,894 shares during the period.

Silk Road Medical Price Performance

SILK traded down $0.83 on Friday, reaching $21.39. The company had a trading volume of 540,539 shares, compared to its average volume of 742,197. The company has a debt-to-equity ratio of 0.52, a current ratio of 11.05 and a quick ratio of 9.62. Silk Road Medical, Inc has a 1 year low of $6.08 and a 1 year high of $34.13. The stock has a 50-day moving average price of $20.08 and a 200-day moving average price of $16.40.

Silk Road Medical (NASDAQ:SILKGet Free Report) last issued its quarterly earnings data on Tuesday, April 30th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.04. Silk Road Medical had a negative return on equity of 35.47% and a negative net margin of 29.02%. The company had revenue of $48.50 million during the quarter, compared to analysts’ expectations of $44.67 million. The firm’s revenue for the quarter was up 20.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.43) earnings per share. On average, equities analysts predict that Silk Road Medical, Inc will post -1.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on SILK shares. Stifel Nicolaus lifted their price target on Silk Road Medical from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. raised their price objective on Silk Road Medical from $19.00 to $21.00 and gave the company a “neutral” rating in a report on Wednesday, May 1st. Argus raised shares of Silk Road Medical from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Thursday, March 7th. Finally, Piper Sandler raised their price target on shares of Silk Road Medical from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Wednesday, May 1st. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, Silk Road Medical has a consensus rating of “Hold” and a consensus target price of $20.10.

View Our Latest Report on Silk Road Medical

Silk Road Medical Company Profile

(Free Report)

Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure.

Featured Stories

Want to see what other hedge funds are holding SILK? Visit to get the latest 13F filings and insider trades for Silk Road Medical, Inc (NASDAQ:SILKFree Report).

Institutional Ownership by Quarter for Silk Road Medical (NASDAQ:SILK)

Receive News & Ratings for Silk Road Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silk Road Medical and related companies with's FREE daily email newsletter.